PYMXQ Stock UPDATES Polymedix Inc (PYMXQ) 0.0130 10/23/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 23, 2014 at 8:04 AM

Polymedix Inc (PYMXQ) 0.0130 $PYMXQ

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
PFE: 28.30 (+0.02), GSK: 44.41 (+0.78), LPTN: 3.10 (unch), OMER: 11.76 (-0.36), AGN: 182.81 (-3.35), JNJ: 101.22 (+0.86)

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dnrjr/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. M Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and unive

Global Respiratory Tract Infections Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hml3h6/respiratory_tract) has announced the addition of the "Respiratory Tract Infections - Pipeline Review, H1 2013" report to their offering. 'Respiratory Tract Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections. - A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.
TGEN: 5.89 (+0.23), GSK: 44.41 (+0.78), IBIO: 1.77 (+0.03)

Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
TTPH: 23.41 (-0.48), EBS: 21.31 (+0.10), PIP: 1.74 (+0.02), IBIO: 1.77 (+0.03), OGEN: 0.95 (-0.09), ARDM: 8.13 (-0.19)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vuzix to Reveal Q3 2026 Results in Upcoming Call

Vuzix Sets the Stage for Its Q3 2026 Earnings Call Out of all the snazzy tech plays you scribble down on a placemat over morning coffee, Vuzix Corporation (NASDAQ: VUZI) is gearing up for some spotlight action. This November 12, at 4:30 PM Eastern Time, they’re unveiling their third quarter 2026 earnings results, piping hot through a conference call. It's the kind of...

Jay Group Expands to Houston with New Fulfillment Hub

Jay Group's Bold Move in the Logistics Arena In a no-holds-barred expansion, Jay Group's got themselves a brand new sprawling 250,000-square-foot fulfillment hub deep in the heart of Houston. Now, folks, this isn’t just another warehouse. We're talking a 3PL powerhouse that allows coast-to-coast delivery, hitting 90% of U.S. consumers in just a couple of days. If you're...

KLC's TTV Solutions Power Up AI and EV Innovation

Thermal Management: The Unsung Hero When it comes to pushing the boundaries of AI and electric vehicles (EVs), it's the behind-the-scenes tech that counts. KLC Corporation of Taiwan throws the spotlight on their Thermal Test Vehicle (TTV) solutions, proving that heat management isn't just a necessary evil—it's a competitive advantage. KLC's Role in the Semiconductor...

Hehe Forum Stirs Global Harmony in Taizhou, China

Reflecting on Hehe Culture's Impact Seems like everyone and their neighbor are flocking to Taizhou for the annual Hehe Culture Forum. It's not your run-of-the-mill gathering; more than 220 folks from 23 different countries showed up, diving deep into the murky waters of cultural exchange, global governance, and international cooperation. Now, if you think it's just...

Cineverse Hits Record Sales with ‘Pan's Labyrinth’

A Cinematic Blast from the Past There's something almost poetic about the way Guillermo del Toro's 2006 classic, Pan's Labyrinth, is staging a triumphant return to the homes of movie enthusiasts worldwide. It's got all the makings of a tale worth watching—magic meets mayhem, ambition meets art—and now, it's positioning Cineverse (NASDAQ:CNVS) with some eye-popping...

wagamama Spruces Up U.S. Market with mamago Launch

What's Cooking at wagamama with mamago? Here comes wagamama, striding into the American dining scene with that familiar bold Pan-Asian flair, now offering more than just a seat at their tables. The fresh move to a direct-to-door model dubbed ‘mamago’ ushers in an era where their signature dishes don't just seduce your taste buds at their restaurants. Nope, they are...

TIOmarkets App Unveils Enhanced Trading Features

Trading on the Go Takes a Leap Forward Pretty slick development from TIOmarkets, if I do say so myself. They've rolled out a major expansion of their mobile trading app, now packing some hefty features like Depth of Market and more granular order controls right from those little devices in our pockets. Quite the leap if you're one of those folks who can't keep your eyes...

Spotting Alzheimer's: Holiday Visits Might Reveal More

The Unspoken Truth of Holiday Reunions Is there any better barometer than a holiday visit to gauge how your parents are truly doing? Most of us are zooming in, lugging our baggage through the front door and finding Dad telling the same old story not once, not twice, but three solid times at the table. Then there’s Mom, fumbling her way through that pie recipe she could...

Duolingo Lawsuit Looms Over Securities Allegations

Duolingo Lawsuit: A New Headache for Investors Seems like every time you blink, another tech darling is getting dragged to court, and now it's Duolingo's turn to face the music. They're locked in a class action lawsuit food-fight over violations of the Securities Exchange Act of 1934, specifically, §§10(b) and 20(a), and Rule 10b-5. The Core of Allegations Against...

FMC Corporation's Q3 2026: Tough Quarter, Dim Outlook

FMC's Challenging Third Quarter Let's cut through the red tape right away—FMC Corporation just rolled out its Q3 2026 results, and boy, it wasn't pretty. Revenue plummeted to $106 million—a staggering drop from the $542 million of the same quarter last year. If you're wondering how such a bruising came about, you can thank the hefty commercial actions they pulled out...